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his associate, Robert A. Flanders, established 
two irrevocable trusts at Penn. In fall 2003, the 
School honored Walter by naming its research 
center the Walter Flato Goodman Center for 
Comparative Medicine and Genetics, dedicated 
to clinical and basic research for companion 
animals with diseases that parallel those in 
humans. ■
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Genetic Therapy Reverses Nervous System Damage
By Greg Lester
By injecting a therapeutic gene directly into 
the brain, researchers have treated a naturally 
occurring genetic disease in cats. This is the ﬁrst 
genetic disease affecting the central nervous 
system to be successfully treated in an animal 
larger than mice and rats. If this approach 
can be applied successfully to humans, say the 
researchers, it might one day treat an entire class 
of diseases called lysosomal storage disorders, 
which cause severe, sometimes fatal, disabilities 
in about one in 5,000 births. The members 
of the research team from the University of 
Pennsylvania School of Veterinary Medicine, the 
Children’s Hospital of Philadelphia, and the U.S. 
Naval Academy published their ﬁndings in the 
March 2005 Annals of Neurology. 
The animals involved in the study are born 
with a genetic disorder directly analogous to 
alpha-mannosidosis, or AMD, an inherited 
disease in humans that causes severe mental 
retardation and skeletal abnormalities. Cats 
with AMD do not live more than six months. 
Children born with the worst form of the disease 
rarely survive into their teens. 
“Through gene therapy, we replace a ‘broken’ 
gene responsible for alpha-mannosidase with the 
correct, functioning copy, to dramatic results,” 
said John H. Wolfe, professor of pathology and 
medical genetics at the School of Veterinary 
Medicine and a neurology researcher at Chil-
dren’s Hospital. “The treated cats were markedly 
improved compared to diseased cats, with better 
balance and muscle control and fewer tremors.” 
Although the disease itself is rare, AMD is 
one of about 50 lysosomal storage diseases, a 
class of diseases that accounts for a signiﬁcant 
portion of the instances of mental retardation 
in children. Other examples include Tay-Sachs 
disease, Hunter disease, and Pompe disease. In a 
lysosomal storage disease, cellular debris accumu-
lates within storage areas of cells called lysosomes. 
In the case of AMD, children are born with a 
faulty version of the gene for an enzyme called 
lysosomal alpha-mannosidase, or LAMAN. 
“Shortly after birth, brain tissue is still 
physically maturing, which means that there is a 
particularly important window of opportunity 
for gene therapy in infants,” Dr. Wolfe said. “In 
our study, we could see that gene therapy used 
during this particular time led to a restoration of 
damaged neurons, even though the lesions that 
represent the disease were already extensive.”
According to Charles H. Vite, lead author of 
the paper and assistant professor of veterinary 
neurology at Penn, the treated cats not only 
demonstrated dramatic clinical improvement, 
but MRI also revealed that white matter tracks, 
myelin, in the brain had been largely restored. 
“As we move toward the clinical use of this 
therapy in humans, we must develop and utilize 
noninvasive methods to monitor the regression 
of the disease following treatment,” Dr. Vite said. 
“The ability to monitor the improvement in brain 
myelination in alpha-mannosidosis using imaging 
allows the clinician to see improvement in brain 
pathology without the need for brain biopsy.”
The large-animal study also demonstrated 
that only a limited number of injections are 
necessary to introduce the working LAMAN 
gene, one of the ﬁrst steps that will prepare 
this particular gene therapy for practical use in 
humans. The gene is transported via a neutral-
ized virus that “infects” cells with the functioning 
gene. Since the blood-brain barrier would block 
the virus carrying the gene if it were circulating 
in the bloodstream, the researchers injected the 
virus directly into the brain.
“The brain of the cat is much closer in size 
to the human infant brain compared to mice. 
Thus we think that it may be possible to achieve 
similar results in humans with as few as 20 to 30 
injections in each of the two hemispheres of the 
brain,” Dr. Wolfe said. “We believe, however, we 
can further limit the number of injections by the 
use of strong promoters that could increase the 
amount of enzyme that comes from corrected 
cells.”
Although encouraged by their ﬁndings, 
the researchers note that any clinical trials in 
humans might be years in the future. 
Video comparing a cat with AMD to one that 
had been given gene therapy is available at  
www.mrw.interscience.wiley.com/suppmat/ 
0364-5134/suppmat/2005/57/v57.3.355.html. 
Funding for this research was provided by the 
National Institutes of Health. In addition to Drs. 
Wolfe and Vite, researchers involved in the study 
include Joseph G. McGowan; Sumit N. Niogi; 
Marco A. Passini; Kenneth J. Drobatz, associate 
professor of critical care at the Ryan Hospital; 
and Mark E. Haskins, V’69, professor of pathol-
ogy and medical genetics. ■
In 1936, 14-year-old Walter Flato Goodman 
was vacationing with his family in Paris when he 
saw his ﬁrst Skye terrier, and it was love at ﬁrst 
sight. When the Goodmans returned to America, 
a Skye puppy was in tow. Thus Walter’s future as 
a one of the world’s most prominent breeder-
owner-handlers of Skyes was born.
Since that day, Walter and his terriers have 
won 99 Best in Show awards and 300 Terrier 
Group First awards. He is a member of the 
Westbury Kennel Association, the Westminster 
Kennel Club, the Palm Beach County Dog 
Fanciers Association, and The Kennel Club (of 
England). Walter is President and Chief Steward 
of the Montgomery County Kennel Club in 
Pennsylvania, which holds the world’s largest 
annual terrier show. As the Delegate of the Skye 
Terrier Club of America, he is a member of the 
Board of Directors of the American Kennel Club. 
Since 1975, Walter has been approved to judge 
Best in Show, the Terrier Group, and Junior 
Showmanship competitions. 
Walter has long supported the School; he 
joined its Board of Overseers in 1986, and, with 
Walter Goodman (left) with his Skye terrier “Evie,” who was 
judged Best in the Terrier Group by Jeremiah O’Callaghan at 
the 1957 show of the Kennel Club of Philadelphia.
Walter Goodman and Skye Terriers:  
“Love at First Sight”
